Zevra Therapeutics price target raised to $19 from $18 at Citizens JMP

Citizens JMP analyst Jason Butler raised the firm’s price target on Zevra Therapeutics (ZVRA) to $19 from $18 and keeps an Outperform rating on the shares. Zevra reported Q1 results and said the MIPLYFFA launch continues to exceed expectations, with 122 patient enrollment forms received, up from 109 at the end of December, the analyst tells investors in a research note. It is “highly encouraging” that new patient enrollment forms continue to increase beyond the cohort of patients in the U.S. extended access program, the firm says.